Suppr超能文献

在等待肺移植的患者中使用二氧化碳清除设备:初步经验。

The use of CO2 removal devices in patients awaiting lung transplantation: an initial experience.

作者信息

Ricci D, Boffini M, Del Sorbo L, El Qarra S, Comoglio C, Ribezzo M, Bonato R, Ranieri V M, Rinaldi M

机构信息

Division of Cardiac Surgery, San Giovanni Battista Hospital Molinette, University of Torino, Torino, Italy.

出版信息

Transplant Proc. 2010 May;42(4):1255-8. doi: 10.1016/j.transproceed.2010.03.117.

Abstract

BACKGROUND

Lung transplantation is the treatment of choice for patients with end-stage lung failure. Limitations are presented by the shortage of donors and the long waiting list periods. New techniques, such as extracorporeal membrane ventilator devices with or without pump support, have been developed as bridges to transplantation for patients with severe, unresponsive respiratory insufficiency.

METHODS

Between November 2005 and September 2009, 12 patients (7 males and 5 females), of overall mean age of 43.3 +/- 15.5 years underwent decapneization with extracorporeal devices. In 6 cases, a NovaLung system was used; in the remaining 6 patients, it was a Decap device. Causes of respiratory failure that led to implantation of such devices were cystic fibrosis (n = 6), pulmonary emphysema (n = 5), and chronic rejection of a previous double lung transplant (n = 1).

RESULTS

Mean time on extracorporeal decapneization was 13.5 +/- 14.2 days. Eight patients died on the device. Three patients were bridged to lung transplantation; 1 recovered and was weaned from the device after 11 days. Mean PaCO(2) on the extracorporeal gas exchanger was significantly lower for both the devices at 24, 48, and 72 hours after implantation (P < .05). No significant difference was observed for the 2 systems.

CONCLUSION

In our initial experience, decapneization devices have been simple, efficient methods to support patients with mild hypoxia and severe hypercapnia that is refractory to mechanical ventilation. This could represent a valid bridge to lung transplantation in these patients.

摘要

背景

肺移植是终末期肺功能衰竭患者的首选治疗方法。供体短缺和漫长的等待名单周期带来了限制。新技术,如带有或不带有泵支持的体外膜肺氧合装置,已被开发出来作为严重、无反应性呼吸功能不全患者移植的桥梁。

方法

2005年11月至2009年9月期间,12例患者(7例男性和5例女性),总体平均年龄为43.3±15.5岁,接受了体外装置辅助下的无自主呼吸治疗。6例使用了诺瓦肺系统;其余6例患者使用的是脱机装置。导致植入此类装置的呼吸衰竭原因包括囊性纤维化(n = 6)、肺气肿(n = 5)和先前双肺移植的慢性排斥反应(n = 1)。

结果

体外无自主呼吸治疗的平均时间为13.5±14.2天。8例患者在装置上死亡。3例患者成功过渡到肺移植;1例患者康复并在11天后脱离装置。植入后24、48和72小时,两种装置在体外气体交换器上的平均动脉血二氧化碳分压均显著降低(P <.05)。两种系统之间未观察到显著差异。

结论

根据我们的初步经验,无自主呼吸装置是支持轻度低氧血症和机械通气难治性严重高碳酸血症患者的简单、有效方法。这可能是这些患者肺移植的有效桥梁。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验